International Biotechnology Trust
International Biotechnology Trust, established in 1994 and based in Wales, United Kingdom, provides investors with access to the rapidly growing biotechnology sector through an actively managed, diversified fund. The trust is managed by a team from SV Health Investors, with over 60 years of combined experience in the field. It invests primarily in a diverse portfolio of global quoted biotechnology stocks, while also including selected unquoted investments aimed at delivering long-term returns. The investment strategy focuses on excellent management teams, innovative products, and strong potential for outperformance. Under the leadership of Lead Investment Manager Carl Harald Janson, the trust has achieved notable performance, significantly surpassing its benchmark and the FTSE All-Share Index over recent years. International Biotechnology Trust aims to deliver both high capital growth and sustainable dividend income, appealing to investors interested in the biotechnology landscape.
Autifony Therapeutics
Series A in 2015
Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative medicines for hearing disorders, including hearing loss and tinnitus. Established in 2011, the company leverages a drug discovery platform aimed at addressing unmet medical needs in this area. In addition to its primary focus on hearing-related conditions, Autifony's platform is also designed to alleviate symptoms associated with central nervous system disorders such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By concentrating on these conditions, Autifony Therapeutics aims to provide effective treatment options for patients suffering from a range of debilitating disorders.
Karus Therapeutics
Series B in 2012
Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, focused on developing innovative small molecule drugs for cancer treatment. Established in 2005, the company specializes in orally-active drugs that target specific molecular pathways. Its portfolio includes KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, aimed at treating both hematological and solid tumors, and KA2507, which targets HDAC6 for PD-L1 expressing tumors. Karus Therapeutics combines targeted therapies with immunotherapeutic activity, enabling effective treatment of a variety of cancers as well as immune and inflammatory disorders.
Oxagen Limited is a biopharmaceutical company focused on developing and commercializing anti-inflammatory medications for asthma and other chronic allergic conditions. The company specializes in small molecule drugs, including OC000459, an oral CRTH2 antagonist aimed at treating eosinophilic asthma and allergic rhinoconjunctivitis. Oxagen's drug development targets the CRTH2 receptor, which plays a critical role in the initiation and maintenance of allergic responses. In addition to asthma, their pipeline includes treatments for autoimmune diseases, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Founded in 1996 and based in London, Oxagen serves customers in the United Kingdom, Russia, and other countries in the Commonwealth of Independent States.
Sutro Biopharma
Venture Round in 2007
Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.
GlycoFi is a biotech firm based in Lebanon, New Hampshire, focused on developing biotherapeutics through its innovative glycan optimization technology. The company has engineered a library of yeast strains that enable precise human glycosylation, resulting in therapeutic proteins suitable for drug development. GlycoFi aims to establish its own pipeline of therapeutic products while also collaborating with other pharmaceutical companies to enhance their drug offerings. Founded in 2000, GlycoFi operates as a subsidiary of Merck & Co., Inc., further expanding its capabilities in the biotherapeutics landscape.
Oxagen Limited is a biopharmaceutical company focused on developing and commercializing anti-inflammatory medications for asthma and other chronic allergic conditions. The company specializes in small molecule drugs, including OC000459, an oral CRTH2 antagonist aimed at treating eosinophilic asthma and allergic rhinoconjunctivitis. Oxagen's drug development targets the CRTH2 receptor, which plays a critical role in the initiation and maintenance of allergic responses. In addition to asthma, their pipeline includes treatments for autoimmune diseases, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Founded in 1996 and based in London, Oxagen serves customers in the United Kingdom, Russia, and other countries in the Commonwealth of Independent States.
Aderis Pharmaceuticals
Series D in 2001
Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cardio-renal diseases. The company's product pipeline features adenosine agonists and antagonists aimed at treating cardiovascular conditions, alongside leukotriene synthesis inhibitors for chronic renal diseases. Aderis focuses on creating small-molecule, receptor-specific therapeutics that modulate the activity of proteins like adenosine and dopamine, thereby enhancing therapeutic effects while reducing side effects. Additionally, Aderis has established license agreements with strategic partners for advanced products targeting Parkinson's disease and for the diagnosis of coronary artery disease.
eBioinformatics
Venture Round in 2000
eBioinformatics is a Bioinformatics Service Provider. They deliver innovative and broad-ranging bioinformatics services to the worldwide bioscience research effort. The difficulty of managing the flood of data generated by biomedical and biotechnology research is the inspiration behind eBioinformatics ' products. eBioinformatics emphasises accessibility and usability so that bioscientists, whether they are working in academic, government or corporate research, are empowered by the ability to analyze and manage the large quantities of data they produce.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.